Zota is aiming to establish itself as a major pharmaceutical manufacturer brand in next 3-4 years

Bengaluru, March 02, 2016:

1. What is the entire size of the pharma industry as of now?

Indian Pharmaceutical Market is approx US $20 billion out of which domestic generic drug accounts US $13.1 billion. Global pharmaceutical market is expected to cross US $1.3 trillion by 2018.

2. What will the healthcare industry’s future be in the coming 10-15 years?

Indian Pharmaceutical Market is likely to get boost in short span of 4-5 yrs with Make in India initiative and government’s plan to make india as Manufacturing hub.

From Long term perspective biotechnology would be the focus. Extensive use of biotechnological products and biopharmaceuticals products are in focus. Many companies have extended their forays into this area.

Development of biosimilars

Health Insurance would also play a major role as capability to spend more on healthcare needs would increase.

Because of patent cliff there would be downfalls in revenue for R&D oriented companies, whereas generic players would leverage this opportunity, to stabilize loss of revenue to the entire market.

3. What is the space ZOTA has in the healthcare segment?

Zota healthcare has expanded its arms to all the potent segments of healthcare industry say for eg. Cardiovascular and diabetic care, psychological and neurological disorder, respiratory care, gastrointestinal care and orthopedic care covering all major therapeutic class of medicines to general use medicines also

Zota healthcare has strong presence in nutraceuticals segment having 6 patents and as many as 16 lined up for approval.

Zota healthcare is also into exports of pharmaceutical products also

4. What is ZOTA’s game plan in terms of branding and positioning and how will it be handled?

Zota is aiming to establish itself as a major pharmaceutical manufacturer brand in next 3-4 years for which the company has already appointed a professional marketing agency which looks after its branding and other marketing activities. The company also plans to integrate itself with various activations to uplift the brand with the help of the agency. As of now the company has already started the process of rebranding itself from its previous image to bring a freshness to the brand and give a new meaning to it by adapting itself to the changing market trends and long term vision of the company.

5. What are the challenges of this industry?

Dumping of fake and low standards of medicines by neighboring countries and a few domestic players are posing a serious challenge to the industry.

Indian Regulatory guidelines are far behind to benchmark and other developed countries

Patent and innovation protection

FDI policy

Drug Pricing. In 2013, Drug Pricing control order was amended and ceiling price was for 348 molecules were fixed. By the time entire industry coped up with those changes, new molecules are added thus have to re-strategize frequently

Poor Patent and other intellectual property protection

Lack of common centralized taxation regime

 

Corporate Comm India (CCI Newswire)